Best Read Articles on News Not Related to COVID-19 in 2021
Apotex's importation of Chantix (varenicline) and Express Scripts' formulary exclusions were among the best read articles this year that didn't concern COVID-19.
FDA Approves Generic of Chantix, Pfizer's Smoking Cessation Drug
This is the first approval of generic version of Chantix, and it comes just weeks after a recall of the brand-name drug.
Apotex to Import Generic of Chantix from Canada
This is being done in coordination with the FDA to address the shortage created by the recall of Chantix.
Express Scripts Releases List of 2022 Formulary Exclusions
Four products on the preferred list this year will be excluded next year.
Nonopioid Pain Therapeutic Achieves More Than 100 Formulary Approvals
Anjeso, a COX-2 inhibito, is a faster-acting injectable formulation of meloxicam. As amnm alternative to opiods, it reduces opioid use after surgery.
FDA approves sNDAs for Vazalore
Application was submitted for both the 81 and 325 mg doses of the liquid-filled capsule formulation of aspirin.
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More
